Shattuck Labs' (STTK) Buy Rating Reaffirmed at HC Wainwright

Shattuck Labs (NASDAQ:STTK - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They currently have a $28.00 target price on the stock. HC Wainwright's price objective would suggest a potential upside of 243.14% from the company's current price.

Separately, Needham & Company LLC reiterated a "buy" rating and set a $12.00 price target on shares of Shattuck Labs in a research report on Tuesday.

Shattuck Labs Stock Down 3.8 %

Shares of Shattuck Labs stock traded down $0.32 during trading on Wednesday, reaching $8.16. 577,963 shares of the stock were exchanged, compared to its average volume of 369,609. Shattuck Labs has a 1 year low of $1.33 and a 1 year high of $11.76. The firm has a market cap of $388.01 million, a price-to-earnings ratio of -4.23 and a beta of 1.98. The stock's fifty day moving average is $9.55 and its 200 day moving average is $7.46.

Shattuck Labs (NASDAQ:STTK - Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The company had revenue of $1.15 million during the quarter, compared to analyst estimates of $0.30 million. Shattuck Labs had a negative return on equity of 64.85% and a negative net margin of 3,133.63%. The company's revenue was up 2200.0% compared to the same quarter last year. Equities analysts forecast that Shattuck Labs will post -1.56 earnings per share for the current year.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, insider Stephen Stout sold 16,004 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $10.53, for a total value of $168,522.12. Following the completion of the transaction, the insider now owns 74,437 shares in the company, valued at $783,821.61. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 10.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Shattuck Labs

Hedge funds and other institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC raised its stake in Shattuck Labs by 4.8% during the first quarter. SG Americas Securities LLC now owns 39,377 shares of the company's stock valued at $352,000 after buying an additional 1,788 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in Shattuck Labs by 79.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,553 shares of the company's stock valued at $97,000 after purchasing an additional 5,989 shares during the last quarter. Cannon Global Investment Management LLC purchased a new position in shares of Shattuck Labs in the first quarter worth $91,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Shattuck Labs in the first quarter worth $174,000. Finally, Reliant Investment Management LLC bought a new position in shares of Shattuck Labs during the fourth quarter valued at $143,000. Hedge funds and other institutional investors own 58.74% of the company's stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.